Buehler Kevin
Known title: DirectorCIK: 0001792722
Buehler Kevin's purchase track record
How the stock did after each of Buehler Kevin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 27, 2024
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+1.2%
3 months: +1.1%
Beat the S&P 500
0%
median -10.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/25/2025 | DTIL | $21K | +21.0% | +1.2% | +13.8% |
| 3/26/2025 | DTIL | $21K | -6.4% | +13.3% | +16.2% |
| 12/27/2024 | DTIL | $21K | +1.1% | -7.5% | +3.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DTIL | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 | View on chart |
| DTIL | ▲ Buy | Open Market | 5,076 | $21K | 6/25/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 4,523 | $21K | 3/26/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 4,320 | $21K | 12/27/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 5,701 | — | 4/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.